ArticleChest2025
Association of Anti-Ro52 Seropositive Interstitial Lung Disease With a Higher Risk of Disease Progression and Mortality.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Integration of clinical variables and CT radiomics features in a nomogram for predicting interstitial lung disease in Sjögren's syndrome.Journal of thoracic disease · 2026Article
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Beyond IPF: Pulmonary Function Test Predictors of Echocardiographic Pulmonary Hypertension Across the Spectrum of ILD.Pulmonary circulation · 2026Article
- Tripartite motif containing 21 autoimmunity primes CD8Arthritis research & therapy · 2026Article
- Anti-Ro-52 antibody is a risk factor for recurrence in interstitial lung disease with positive anti-aminoacyl tRNA synthetase antibody: a single-center, retrospective observational study.BMC pulmonary medicine · 2026Observational
- Distinct phenotypes and prognosis between Jo-1 and non-Jo-1 subtypes in anti-synthetase syndrome: a retrospective cohort study from China.Clinical rheumatology · 2026Article
- Beyond overlap: a Ro52-driven glandular-pulmonary phenotype at the interface of Sjögren disease and anti-synthetase syndrome in a multicentre cohort.Frontiers in immunology · 2026Article
- Multicenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti-Ro/La Antibody Detection in Primary Sjögren's Syndrome.Journal of immunology research · 2026Article
- Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms.Frontiers in immunology · 2026Article
- Immunopathogenic Mechanisms in Connective Tissue Disease-Associated Interstitial Lung Disease: Incessant Loop of Immunity to Fibrosis.International journal of molecular sciences · 2025Review
- Treatment Algorithms for Inflammatory Myopathies in Adults: from Guidelines to Clinical Practice.Current treatment options in rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIdentifying biomarkers is vital for interstitial lung disease (ILD) management and prognostication. Although anti-Ro52 antibodies frequently are detected in autoimmune diseases, their significance in ILD remains unclear. RESEARCH QUESTION: What is the prognostic significance of anti-Ro52 antibody positivity in patients with ILD? STUDY DESIGN AND
methodsThis retrospective cohort study used an ILD registry of patients seen at an academic tertiary hospital's ILD clinic between 2015 and 2024. All patients with a diagnosis of ILD and tested for anti-Ro52 antibody status were divided into anti-Ro52 positive and negative groups. The primary outcome was ILD progression or all-cause death. ILD progression was defined as any of the following: hospitalization because of ILD, absolute decline in FVC of ≥ 10% predicted from baseline, or lung transplantation. The Kaplan-Meier method and Cox proportional hazards regression model were used for survival analysis.
resultsOf 1,026 patients tested for the anti-Ro52 antibody (median age, 70 years; 52% male), 154 patients (15%) showed positive anti-Ro52 results. Underlying ILD subtypes were as follows: interstitial pneumonia with autoimmune features (n = 489 [48%]), connective tissue disease-associated ILD (n = 132 [13%]), idiopathic pulmonary fibrosis (n = 103 [10%]), hypersensitivity pneumonitis (n = 61 [6%]), and other idiopathic ILD (n = 241 [24%]). The anti-Ro52-positive group was younger (median age, 67 years vs 70 years), was more likely to have connective tissue disease (28% vs 10%), and more frequently showed copositive results for myositis-specific antibody (29% vs 16%). After a median follow-up of 25.6 months, patients with positive anti-Ro52 findings showed a higher risk of ILD progression or death (hazard ratio, 2.10; 95% CI, 1.61-2.73; P < .001) and showed a higher risk of lung transplantation or death (hazard ratio, 1.61; 95% CI, 1.11-2.35; P = .014) on multivariable analysis.
interpretationOur results indicate that Anti-Ro52-seropositive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.